Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept, Inc. Prices $10,000,000 Public Offering
SAN DIEGO , Feb. 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, today announced the pricing of an underwritten public offering of 8,000,000 shares of its
View HTML
Toggle Summary Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer
Company launches blood-based 'liquid biopsy' to identify ROS1 rearrangement and better inform NSCLC treatment decisions
View HTML
Toggle Summary Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients
Blood-Based Liquid Biopsy Technology Launched for Testing Regions of the EGFR Gene Associated With Acquired Resistance in NSCLC Indications
View HTML
Toggle Summary Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment
Companies to Evaluate Expression and Mutation in NSCLC Therapeutic Target ALK
View HTML
Toggle Summary Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network
ACPN's Approximately 19 Million Participants Now Have Access to Biocept's Suite of Blood-Based Diagnostics
View HTML
Toggle Summary Biocept to Present at the 8th Annual OneMedForum
SAN DIEGO, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to
View HTML
Toggle Summary Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells
Biocept's CTC Test Identified Approximately 22 Percent of Women With Breast Cancer to Have HER2 Positive CTC After Disease Progression Following a HER2 Negative Diagnosis With Solid Tumor Biopsy
View HTML
Toggle Summary Biocept Expands Worldwide Microchannel Patent Protection to South Korea
Korean Patent Includes Microfluidic Channel for Capturing Circulating Tumor Cells
View HTML
Toggle Summary Biocept Appoints Experienced Physician as Medical Director
Veena Singh, MD, FCAP, FACMG Brings Years of Medical Experience to Biocept Team
View HTML
Toggle Summary Biocept Reports Third Quarter 2014 Financial Results
SAN DIEGO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30,
View HTML